OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder

Condition:   Opioid-use Disorder Interventions:   Device: OXD01 digital therapy;   Other: Standard of Care Sponsor:   Orexo AB Not yet recruiting

Source: ClinicalTrials.gov - July 1, 2021 Category: Research Source Type: clinical trials